Jeremy Berbereia, PA
Medical · Branson, MONPI 1508279381
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 394 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Abbott at 33.2% of the total.
Across 394 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AstraZeneca$827
- Boston Scientific$753
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$274
- Amgen$271
- Shockwave Medical, Inc$226
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,958100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 132 | $2,313 |
| AstraZeneca | 44 | $827 |
| Boston Scientific | 35 | $753 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $274 |
| Amgen | 20 | $271 |
| Shockwave Medical, Inc | 17 | $226 |
| E.r. Squibb & Sons, L.L.C. | 14 | $223 |
| Pfizer | 25 | $209 |
| Novartis | 12 | $206 |
| Boehringer Ingelheim | 9 | $185 |
| Johnson & Johnson | 11 | $182 |
| Abiomed | 7 | $179 |
| Edwards Lifesciences | 1 | $161 |
| Philips North America LLC | 4 | $132 |
| Biosense Webster, Inc. | 1 | $122 |
| Novo Nordisk | 6 | $93 |
| Cardiovascular Systems Inc. | 7 | $93 |
| Sanofi-aventis U.S. LLC | 2 | $67 |
| Lexicon Pharmaceuticals, Inc. | 3 | $65 |
| Merck | 4 | $62 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $54 |
| Bayer | 3 | $48 |
| Sanofi | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $22 |
| Cordis US CORP. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Heartflow, Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Elutia, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,958 in reported general payments places this provider in the 85th percentile of 198 medical providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 950 | $772,938 |
| XareltoRivaroxaban | 255 | $206,002 |
| EntrestoSacubitril/Valsartan | 175 | $175,290 |
| FarxigaDapagliflozin Propanediol | 85 | $58,432 |
| BrilintaTicagrelor | 108 | $56,824 |
| Repatha SureclickEvolocumab | 43 | $43,422 |
| OzempicSemaglutide | 17 | $26,237 |
| MultaqDronedarone Hcl | 26 | $24,700 |
| Praluent PenAlirocumab | 24 | $15,638 |
| JardianceEmpagliflozin | 11 | $11,147 |
| Repatha SyringeEvolocumab | 18 | $10,733 |
| Metoprolol Succinate | 678 | $8,041 |
| Ranolazine ErRanolazine | 77 | $5,229 |
| TradjentaLinagliptin | 11 | $4,988 |
| Atorvastatin Calcium | 670 | $4,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $209 | $772,938950 claims |
| Johnson & JohnsonXarelto | $182 | $206,002255 claims |
| NovartisEntresto | $206 | $175,290175 claims |
| AstraZenecaFarxiga, Brilinta | $827 | $115,256193 claims |
| Novo NordiskOzempic | $93 | $26,23717 claims |
| Sanofi-aventis U.S. LLCMultaq | $67 | $24,70026 claims |
| Boehringer IngelheimJardiance, Tradjenta | $185 | $16,13522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 medical providers in Missouri.
Other medical in Branson
- Kelly MartiBranson$6K
- Melanie ChisamSpringfield$92K
- Emily JensenBowling Green$51K
- Sarah WilmsmeyerChesterfield$22K
- Amy MosmanSaint Louis$21K
- Dustin BartlettSpringfield$21K
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Corey WhitesidesColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.